144 related articles for article (PubMed ID: 9488603)
41. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.
Smith IE; Walsh G; Jones A; Prendiville J; Johnston S; Gusterson B; Ramage F; Robertshaw H; Sacks N; Ebbs S
J Clin Oncol; 1995 Feb; 13(2):424-9. PubMed ID: 7844604
[TBL] [Abstract][Full Text] [Related]
42. Randomized study of zorubicin versus zorubicin-cisplatin in undifferentiated carcinoma of the nasopharynx (UCNT).
Jelić S; Kovcin V; Milanović N; Kreacić M; Pendjer I; Jovanović V; Ristović Z; Oprić M; Mitrović L
Ann Oncol; 1997 Aug; 8(8):739-44. PubMed ID: 9332680
[TBL] [Abstract][Full Text] [Related]
43. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.
Huan SD; Stewart DJ; Aitken SE; Segal R; Yau JC
Am J Clin Oncol; 1999 Oct; 22(5):471-4. PubMed ID: 10521061
[TBL] [Abstract][Full Text] [Related]
44. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
Langenbuch T; Mross K; Jonat W; Hossfeld DK
Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Santangelo M; Bucci L; Fei L; Di Martino N; Mantovani G; Caponigro F
Breast Cancer Res Treat; 1995 Sep; 35(3):243-8. PubMed ID: 7579494
[TBL] [Abstract][Full Text] [Related]
46. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.
Sandles LG; Freedman RS; Raber MN; Kavanagh J; Edwards CL; Scott WR; Wharton JT
Gynecol Oncol; 1990 Nov; 39(2):139-45. PubMed ID: 2121628
[TBL] [Abstract][Full Text] [Related]
47. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma.
Jelić S; Kovcin V; Milanović N; Babović N; Kreacić M; Ristović Z; Vlajić M; Filipović-Ljesković I
Eur J Cancer; 1997 Feb; 33(2):220-5. PubMed ID: 9135492
[TBL] [Abstract][Full Text] [Related]
48. Weekly first-line chemotherapy of metastatic breast cancer with cyclophosphamide and epirubicin.
Alba E; Blanco E; Aranda E; Lasso R; Alonso L; Belon J; Garcia A; Sanchez-Chaparro MA; Breton JJ
Tumori; 1992 Oct; 78(5):338-40. PubMed ID: 1494806
[TBL] [Abstract][Full Text] [Related]
49. High-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma.
Jelić S; Vuletić L; Milanović N; Tomasević Z; Kovcin V
Tumori; 1990 Oct; 76(5):467-71. PubMed ID: 2256192
[TBL] [Abstract][Full Text] [Related]
50. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Lissoni P; Tancini G; Paolorossi F; Mandalà M; Ardizzoia A; Malugani F; Giani L; Barni S
J Pineal Res; 1999 Apr; 26(3):169-73. PubMed ID: 10231730
[TBL] [Abstract][Full Text] [Related]
51. Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study.
Gardin G; Barone C; Nascimben O; Ianniello G; Sturba F; Contu A; Pronzato P; Rosso R
Eur J Cancer; 1996 Jan; 32A(1):176-7. PubMed ID: 8695230
[No Abstract] [Full Text] [Related]
52. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
Gadducci A; Brunetti I; Muttini MP; Fanucchi A; Dargenio F; Giannessi PG; Conte PF
Eur J Cancer; 1994; 30A(10):1432-5. PubMed ID: 7833097
[TBL] [Abstract][Full Text] [Related]
53. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial.
Habeshaw T; Paul J; Jones R; Stallard S; Stewart M; Kaye SB; Soukop M; Symonds RP; Reed NS; Rankin EM
J Clin Oncol; 1991 Feb; 9(2):295-304. PubMed ID: 1988576
[TBL] [Abstract][Full Text] [Related]
54. Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.
Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher RI
Cancer Chemother Pharmacol; 1990; 27(1):33-40. PubMed ID: 2245491
[TBL] [Abstract][Full Text] [Related]
55. Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
Stewart DJ; Cripps MC; Goel R; Dahrouge S; Yau J; Tomiak E; Huan S; Soltys K; Prosser A; Davies RA
Cancer Chemother Pharmacol; 1997; 41(1):1-8. PubMed ID: 9443607
[TBL] [Abstract][Full Text] [Related]
56. Dexverapamil to overcome epirubicin resistance in advanced breast cancer.
Thürlimann B; Kröger N; Greiner J; Mross K; Schüller J; Schernhammer E; Schumacher K; Gastl G; Hartlapp J; Kupper H
J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R3-6. PubMed ID: 8698740
[TBL] [Abstract][Full Text] [Related]
57. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
[TBL] [Abstract][Full Text] [Related]
58. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
Silvestrini R; Gornati D; Zaffaroni N; Bearzatto A; De Marco C
Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
[TBL] [Abstract][Full Text] [Related]
59. Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer.
Pacini P; Tucci E; Algeri R; Rinaldini M; Guarnieri A; Valzelli S; Neri B
Eur J Cancer; 1994; 30A(4):460-3. PubMed ID: 7517150
[TBL] [Abstract][Full Text] [Related]
60. Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Popert RJ; Masters JR; Coptcoat M; Zupi G
Urol Res; 1995; 22(6):367-72. PubMed ID: 7740656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
